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Background: We previously found that the low frequency magnetic fields (LF-MF) inhibited gastric and lung cancer
cell growth. We suppose that exposure to LF-MF may modulate immune function so as to inhibit tumor. We here
investigated whether LF-MF can inhibit the proliferation and metastasis of melanoma and influence immune
function.
Methods: The effect of MF on the proliferation, cell cycle and ultrastracture of B16-F10 in vitro was detected by cell
counting Kit-8 assay, flow cytometry, and transmission electron microscopy. Lung metastasis mice were prepared
by injection of 2 × 105 B16-F10 melanoma cells into the tail vein in C57BL/6 mice. The mice were then exposed to
an LF-MF (0.4 T, 7.5 Hz) for 43 days. Survival rate, tumor markers and the innate and adaptive immune parameters
were measured.
Results: The growth of B16-F10 cells was inhibited after exposure to the LF-MF. The inhibition was related to
induction of cell cycle arrest and decomposition of chromatins. Moreover, the LF-MF prolonged the mouse survival
rate and inhibited the proliferation of B16-F10 in melanoma metastasis mice model. Furthermore, the LF-MF
modulated the immune response via regulation of immune cells and cytokine production. In addition, the number
of Treg cells was decreased in mice with the LF-MF exposure, while the numbers of T cells as well as dendritic cells
were significantly increased.
Conclusion: LF-MF inhibited the growth and metastasis of melanoma cancer cells and improved immune function
of tumor-bearing mice. This suggests that the inhibition may be attributed to modulation of LF-MF on immune
function and LF-MF may be a potential therapy for treatment of melanoma.
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The treatment of low frequency magnetic fields (LF-MF)
is thought to be non-invasive and non-ionizing and even
possess non-thermal effects on cells and tissues. Thus the
possible effects of LF-MF on human health have been at-
tractively explored. Interestingly, some studies showed
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reproduction in any medium, provided the oractivity in vitro and in vivo. Sixty Hz sinusoidal MF could
significantly inhibit cell growth and induce apoptosis in
prostate cancer cells by cleaved caspase-3 and accumu-
lated reactive oxygen species [1]. LF-MF (0.5-16.5 Hz)
combined with a static MF could markedly suppress
tumor growth in Ehrlich ascites carcinoma (EAC) model
mice [2]. Recently, advanced hepatocellular carcinoma
patients were treated with intrabuccally administered
amplitude-modulated electromagnetic fields, and results
showed that the treatment exhibited anti-tumor effects as
well as safe and well tolerated [3].
Melanoma, derived from melanocytes, is one of the most
highly invasive and metastatic tumors [4]. The incidence. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cent years [5]. Melanoma can spread "silently" at an early
stage without any symptoms of metastasis, which become
one of the major obstacles for achieving successful clinical
chemotherapy, surgery and radiotherapy for the treatment
of melanoma [6]. Therefore, novel therapeutic strategies
are needed to overcome tumor metastasis and to improve
the survival and prognosis of melanoma patients. Strik-
ingly, it was reported that 50 Hz MF inhibited melanoma
cell survival and reversed resistance to therapy through
up-regulation of the anti-apoptotic protein BAG3 in mel-
anoma cells [7]. The static MF (35 to 120 mT) also inhib-
ited the growth of melanoma cells [8]. In addition, tumor
growth in mice model was suppressed by a weak intensity
MF (1-5 nT) [9]. It is thus obvious that specific frequency
of MF indeed inhibits the growth of melanoma cancer.
Of note, immune system plays a crucial role in protect-
ing the host against cancer. There is strong evidence for
the existence of an effective cancer immunosurveillance
process in human and mice. In tumor bearing host, how-
ever, immune system is often not able to execute effective
responses, primarily because of negative regulatory mech-
anisms employed by growing cancer [10]. As is well
known, regulatory T cell (Treg) is a specialized subset of
CD4 T cells. In certain cancers the increased Treg num-
bers and/or function may promote cancer progression by
interfering with immune surveillance. Increased Treg
numbers correlated with worse prognosis in cancer pa-
tients [11]. The depletion of Treg led to a better anti-
tumor immune response in the murine system [12]. Im-
portantly, the role of MF on immune system had been re-
ported. Phagocyte activity, ROS release and interleukin-1βFigure 1 Magnetic field exposure system.(IL-1β) production were significantly promoted after con-
tinuous exposure to 50 Hz LF-MF (1mT) [13]. MF expos-
ure negatively correlated with NK activity [14]. However,
it is necessary to clarify modulation of MF on immune
system.
We previously developed a revolving magnetic field
system and found that the LF-MF (0.4 T, 7.5 Hz) inhib-
ited gastric and lung cancer cell growth and altered mid-
kine expression in cancer cells [15]. We suppose that
exposure to MF may inhibit tumor growth through acti-
vation of immune system. In the present study, we thus
investigated the effect of MF (0.4 T, 7.5 Hz) on B16-F10
melanoma cells in vitro and B16-F10 melanoma lung
metastasis model in vivo. Furthermore, we examined the
effect of MF on innate immune and adaptive immune




The construction of experimental magnetic fields has
been described previously [15]. As shown in Figure 1,
two pairs of fan-shaped NdFeB permanent magnets
(N45, Innuovo, Dongyang, China) were embedded into a
circular iron plate and arranged to establish MF. The
bottom two magnets rotated at certain frequency driven
by a step motor, which was controlled using a functional
signal generator. The top two magnets rotated synchron-
ously due to the strong magnetic interaction. Magnetic
flux density was measured at the target site using a gauss
meter (HT201, Hengtong, Shanghai, China). MF at the
target site is alternative pulses with a maximum flux
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(7.5 Hz was used in this study based on the previous
experiments). This instrument was fabricated by the
National Laboratory of Solid Microstructures, Nanjing
University (Nanjing, China). Control cells and mice were
placed in a similar apparatus except that there were two
rotating iron plates instead of magnets (sham MF). For
cell experiment, the entire magnetic apparatus was lo-
cated in an environment with humidity and temperature
controller.
Cell culture
B16-F10 melanoma cells were obtained from the Shanghai
Institute of Cell Biology (Shanghai, China). Cells were
grown in RPMI-1640 medium (Gibco, Carlsbad, CA) with
10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA) and
100 U/ml penicillin and 100 U/ml streptomycin
(Amresco, Solon, OH, USA) at 37°C in a water-saturated
atmosphere with 5% CO2.
Cell apoptosis and cell cycle analysis
For cell apoptosis assay, cells were harvested, washed
once with binding buffer (10 mM Hepes, 140 mM NaCl,
2.5 mM CaCl2) and stained with 5 μl Annexin V-FITC
(eBioscience, San Diego, CA) for 15 min and 10 μl propi-
dium iodide (PI, 20 μl g/ml) (eBioscience, San Diego, CA)
for 10 min. For cell cycle analysis, cells were harvested,
washed once with phosphate buffer saline (PBS), and fixed
in 70% ethanol overnight. Staining for DNA content was
performed with 50 mg/ml PI, 2%Triton-×100 and 1 mg/ml
RNaseA for 30 min. Cells were analyzed by flow cytometry.
Cell-cycle modeling was performed with Modfit 3.0 soft-
ware (Verity Software House, Topsham, ME). Three inde-
pendent experiments were carried out for cell apoptosis
and cell cycle detection.
CFSE labeling assay
Resuspend B16-F10 cells in pre-warmed PBS at a final
concentration of 1 × × 101066 / mL。cells/ml Add 2 μL of
5 mM stock 5-(and -6) carboxyfluorescein diacetate succi-
nimidyl ester (CFSE) (Invitrogen, Carlsbad, CA) solution
per milliliter of cells for a final working concentration of
10 μM. Incubate the cells for 15 min at 37°C. Replace the
loading solution with fresh, pre-warmed medium and incu-
bate the cultures for another 30 min at 37°C. Wash the cells
by resuspending the pellet in fresh media. Pellet and resus-
pend the cells in fresh media a further two times. For a total
of three washes. After culture in a 5% CO2 incubator at
37°C for 5 days with sham MF or MF (2 h/day), the prolif-
eration of B16-F10 cells was detected by flow cytometry.
Cell counting Kit-8 assay
Cells (1 × 104 cells per well) were incubated in 96-well
culture plates (Corning Inc., New York, USA) in 100 μLof medium. After culturing for 5 days with sham MF or
MF (2 h/day), 10 μL Cell Counting Kit-8 (CCK-8)
(Dojindo Laboratories, Kumamoto, Japan) was added
into each well. Absorbance was measured at 450 nm
using a microplate reader.
Transmission Electron Microscopy (TEM)
Exponentially growing B16-F10 cells were seeded into
10 cm dishes (Costar). After intermittent exposure to
sham MF or MF for 5 days, cells were harvested, washed
twice, fixed with 4% glutaraldehyde for 2 h, post-fixed
with 1% OsO4, dehydrated in graded concentrations of
ethanol, and then embedded in resin SPI-Pon 812 (Shell
Chemical, Yuhuan, China). Ultra-thin sections were cut
(80 nm), counterstained with lead citrate and uranylace-
tate, and then observed with a Philips CM 12 electron
microscope (Philips, Eindhoven, Holland) at 80 kV. Per-
centage of positive cells in every 500 cells was counted.
Quantitative real time polymerase chain reaction
Total RNA was isolated using Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. A total of 1 μg RNA was used as the template for
single strand cDNA synthesis utilizing random primers
and the Primescript reverse transcriptase (M-MLV, Takara,
Japan). The cDNA was amplified using SYBR green PCR
Mix (iTAP, Bio-Rad) on an ABI step-one plus sequence
detection system (Applied Biosystems, Foster City, CA),
programmed for 95°C for 10 min, then 40 cycles of 95°C
for 15 s, 60°C for 30 s, and 72°C for 30 s. The amplification
results were analyzed using StepOne Software (V2.1, Ap-
plied Biosystems) and the gene of interest was normalized
to the corresponding β-actin results. The primer se-
quences are as following, Bcl2, (sense) 5'-CTCGTCGCTA
CCGTCGTGACTTCG -3' and (anti-sense) 5'-AGATGCC
GGTTCAGGTACTCA GTC-3'; Survivin, (sense) 5'-GTA
CCTCAAGAACTACCGCATC-3' and (anti-sense) 5'-GT
CATCGGGTTCCCAGCCTTCC-3'; β-actin, (sense) 5'-G
CGTGACATCAAAG AGAAGCT-3' and (anti-sense) 5'-
ATGCCACAGGATTCCATACC-3'.
Animals and experimental groups
4-6 week-old female C57BL/6 mice were purchased from
the Animal Research Center of Yangzhou University, PR
China. Mouse care and experimental procedures were
performed under special pathogen-free conditions with
standard rodent chow and water. The experiments were
conducted according to institutional animal ethics guide-
lines. The protocol was approved by the Committee on
the Ethics of Animal Experiments of Nanjing University
Medical School affiliated Drum Tower Hospital ethics
committee.
We induced lung metastases by injection of 2 × 105
B16-F10 melanoma cells into the tail vein. Mice were
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the mice were normal and exposed to sham MF; MF Nor-
mal group (n = 6), the normal mice were exposed to MF;
Sham MF Tumor mice group (n = 17), the mice were in-
duced melanoma lung metastases and exposed to sham
MF; and MF Tumor mice group (n = 17), the mice were
induced melanoma lung metastases and exposed to MF.
Three days after tumor challenged, mice were treated with
sham MF or MF (0.4 T, 7.5 Hz, 2 h/day) for 43 days. The
mice were sacrificed on days 46. Cardiac blood was col-
lected from each mouse and centrifuged at 450 g for
20 min. Serum was obtained and stored at -70°C until use.
The entire spleen, liver, lung, kidney and heart was re-
moved from each mouse and measured. Splenic cells were
collected from each mouse spleen for further experiment.
Immunohistochemistry
Tumor tissues of tumor mice and lung tissues of normal
mice were harvested, fixed in 10% buffered formalin,
dehydrated, bisected, mounted in paraffin, and sectioned
for immunohistochemistry (IHC). Immunostaining was
performed on 6-μm tissue sections using strept-avidin-
biotin staining kit (Boster). For antigen retrieval, slides
were heated by microwave in 0.01 mol/L Tri-sodium cit-
rate buffer. Nonspecific binding sites were blocked with
5% BSA for 30 min and endogenous peroxidase activity
was suppressed by treatment with 3% H2O2 in methanol
for 30 min. Sections were exposed to anti-rabbit poly-
clonal Ki-67 (1:100, Abcam, Cambridge, MA, USA)
overnight at 4°C. 3,3-diamino-enzidine was used as
chromogen (Boster). Counterstaining was done with
hematoxylin. Negative control sections were incubated
with PBS instead of anti-Ki-67 antibodies. In each step,
samples were washed with PBS. Cells in five different
microscope fields of each Ki-67 staining tissue were used
to calculate positive cells.
Cytokines analysis
Serum cytokines were analyzed by the Proteome Profiler
Array ARY006 (R&D systems, Minneapolis, MN, USA)
according to manufacturer’s instructions. Briefly, 1 ml
mixed serum was obtained from five mice of each group.
Serum diluted in 0.5 ml array buffer was mixed with a
15 ml cocktail of biotinylated detection antibodies. The
serum/antibody mixture is then incubated with the mix
buffer. Any cytokine/detection antibody complex present
is bound by its cognate immobilized capture antibody
on the membrane. Following a wash to remove unbound
material, Streptavidin-Horseradish Peroxidase and che-
miluminescent detection reagents were added. Array im-
ages are from 5 min exposures to X-ray film. The array
allows to detect 40 kinds of proteins: CXCL13, C5a, G-
CSF, GM-CSF, CCL1, CCL11, sICAM-1, IFN-γ, IL-1α,
IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-12p70, IL-16, IL-17, IL-23, IL-27, IP-10, CXCL11,
KC, M-CSF, CCL2, CCL12, CXCL9, CCL3, CCL4, CXCL2,
CCL5, CXCL12, CCL17, TIMP-1, TNF-α, and TREM-1.
Integral optical density (IOD) was analyzed by Gel-Pro
Analyzer 4 (Toyobo, Osaka, Japan) software. The IOD of
interest cytokines were normalized to the corresponding
positive control IOD results.Immune cells detection
We For the collection of splenic cells, single-cell suspen-
sion were dissociated by gently pressing the organ
through a fine, 50 μm-nylon mesh, and cells were col-
lected by centrifugation at 300 g for 5 min. Erythrocytes
were removed by treating the splenic cells with red
blood cell lysis buffer (0.15 M NH4Cl, 1.0 mM KHCO3,
0.1 mM Ethylene Diamine Tetraacetie Acid (EDTA),
pH 7.2) for 5 min and washing twice with cold PBS. 1 ×
106 cell were suspended in PBS and incubated with re-
lated anti-mouse antibodies for 30 min at 4°C, then
washed twice with fluorescence activating cell sorter
(FACS) washing buffer. Data were acquired on FACS
Vantage SE (FACSCalibur, Becton Dickinson, San Jose,
CA) and analyzed with CellQuest software (CellQuest
Pro, Becton Dickinson). The following antibodies used
for flow cytometry: anti-CD3-PE-Cy5.5, anti-CD4-FITC,
anti-CD8-PE, anti-CD11c-PE, anti-CD40-APC and anti-
isotype-specific control Abs were purchased from
eBioscience (eBioscience, San Diego, CA). Three inde-
pendent cells were carried out for detection of each im-
mune cell.Statistical evaluation
Values were expressed as mean ± S.E.M. Statistical ana-
lysis was performed using Mann-Whitney U test to com-
pare the mean values between two groups. In case of
survival curve, the data were analyzed by the log-rank
test. Values of P < 0.05 were considered to be statistically
significant. Statistical analysis was done using the SPSS
11.5 software program (SPSS, Chicago, IL).Results
LF-MF inhibits the proliferation of B16-F10 cells
Firstly, we analyzed the effect of LF-MF (0.4 T, 7.5Hz)
on the proliferation of B16-F10 cells using CFSE labeling
assays. As shown in Figure 2A and B, after 5 days expos-
ure, the proliferation of B16-F10 (proliferation index =
9.35) was suppressed by LF-MF compared to sham LF-MF
(proliferation index =14.87). Then, the inhibitory effect of
the MF was confirmed by CCK8 assay and simple cell
counting, and the results showed that LF-MF slightly but
significantly inhibited the proliferation of B16-F10 cells
(Figure 2C).
Figure 2 LF-MF inhibits the proliferation and induce cell cycle arrest in B16-F10 cells. (A) CFSE proliferation assay analyzes the proliferation
of B16-F10 after exposed to sham LF-MF (Con) or LF-MF (2 h/day, 5 days); The means of proliferation index using CFSE assay (B); CCK-8 assay (C)
and simple cell counting (D) detects the cell proliferation in sham LF-MF (Con) and LF-MF (2 h/day, 5 days). (E) Flow cytometric analysis of cell
cycle after exposure to LF-MF for 3, 4 and 5 days. (F) The mean percentage of G1, S and G2 phase cells. All the experiments were repeated three
times. Data are expressed as means ± S.E.M.
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process of cell cycle arrest in vitro
The effect of LF-MF on the process of cell cycle was also
examined. After 3 and 4 days exposure, no difference in
the G0/G1, S, and G2/M was observed between sham LF-
MF group and LF-MF group. While prolong this exposure
to 5 days, the S-phase rate was significantly decreased
from 40.76% to 37.24% and the G2/M-phase rate was sig-
nificantly increased from 8.9% to 11.6% (Figure 2E and F).
The apoptosis cells were slightly increased from 15.98% to
21.36% after 5 days exposure to LF-MF (Additional file 1:
Figure S1A and B). Then we checked the expression of
genes associated with apoptosis, Bcl2 and survivin, and
found that mRNA expressions of the genes were not chan-
ged after exposure to LF-MF (Additional file 1: Figure S1C
and 1D).
LF-MF alters the ultrastructure of B16-F10 cells
The ultrastractural alteration of B16-F10 cells was ob-
served by transmission electron microscopy (TEM) after
exposure to MF for 5 days. Compared with the sham ex-
posed cells, the LF-MF-treated cells were characterized by
chromatin decomposed (white arrow), and the decom-
posed chromatins reached to the boundary of the kar-
yotheca (Figure 3A and B). Also we found that the black
granules, which represent the senescence degree of cells,
were accumulated in cytoplasm (black arrow) in LF-MF-
treated cells (Figure 3C and D).Figure 3 LF-MF alters the utrastructure of B16-F10 cells. Cell ultrastruc
(A) 500×; (C) 1000×; Cell ultrastructure of B16-F10 cells exposure to LF-MF,
microscopy. Percentage of positive cells in every 500 cells were counted (E
the breaking down of chromatin (white arrow) and black granule accumulLF-MF raises survival rate and inhibit tumor proliferation
in mice model
To investigate whether the LF-MF influences the growth
of B16-F10 cells in vivo, we constructed the lung
metastasis of melanoma mice model. Normal mice and
tumor-bearing mice were exposed to sham LF-MF and
LF-MF (0.4 T, 7.5Hz), respectively. After exposure to
LF-MF for 43 days (2 h/day), the sham tumor-bearing
mice group experienced 58.8% mortality, while LF-MF
tumor-bearing mice group only showed 41.2% mortality,
and the normal mice showed no mortality after sham
LF-MF or LF-MF treatment (Figure 4A). HE and im-
munohistochemistry analysis of lung showed that the
numbers of Ki-67 positive cells were significantly
higher in tumor-bearing mice groups than normal mice
groups, whereas LF-MF tumor-bearing mice group
showed a lower number of Ki-67 positive cells, com-
pared with the sham LF-MF tumor-bearing mice group
(Figure 4B and C).
Next, we detected the alteration of the organs in
mice. After challenged with B16-F10 cells, a significant
tumefaction was showed in spleen and kidney, while
this abnormal tumefaction could be reversed after ex-
posure to LF-MF (Additional file 2: Figure S2A, B and
E). The masses of lung, liver, and heart were mildly al-
tered in both normal mice and tumor-bearing mice
after LF-MF exposure (Additional file 2: Figure S2C, D
and F).ture of B16-F10 cells exposure to Sham LF-MF, original magnification
(B) 500×; (D) 1000×. Cells were observed by transmission electron
). Compared with control cells, the treated cells were characterized by
ation (black arrow).
Figure 4 LF-MF raises survival rate and inhibit tumor proliferation in vivo. (A) Statistical analysis of survival after intravenous challenge of
C57BL/6 mice with B16-F10 cells, and treated with LF-MF. Mice were treated byLF-MF for 43 days, 2 h/day; (B) HE of mice lung in different groups.
(C) Immunohistochemistry analyzes the expression of Ki-67 in tumors of tumor-bearing mice and in lungs of normal mice. (D) Proportion of Ki-67
positive cells in different groups. Five different microscope fields of each group were examined for Figure 4B and C, and cells in five different
microscope fields of each Ki-67 staining tissue were used to calculate positive cells in Figure 4D.
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cytokines in mice serum
Since LF-MF inhibited the growth of B16-F10, we next
attempted to clarify the effect of the LF-MF on immune
response. Inflammatory cytokines in mice serum were
measured by Proteome Profiler Array. After mice chal-
lenged with B16-F10, the cytokines production was to-
tally changed. Compared with the sham LF-MF normal
mice group, amount of some cytokines was increased in
sham LF-MF tumor-bearing mice, including CXC che-
mokine ligand (CXCL)13, CC chemokine ligand (CCL)
1, interleukin (IL)-1β, IFN-γ-inducible protein (IP)-10,
CXCL9, triggering receptor expressed on myeloid cells
(TREM)-1, CCL12, granulocyte colony-stimulating fac-
tor (G-CSF), IL-1rα and IL-16, while only few cytokines
were decreased, including CCL11, CCL5 and CXCL12
(Figure 5A, C, E and F). The LF-MF also influenced pro-
duction of cytokines. In normal mice groups, CXCL13,
CCL11, CCL5, G-CSF, IL-1ra and IL-16 were up-
regulated and CCL1, IFN-γ, CXCL12 and KC were
down-regulated after LF-MF exposure (Figure 5A, B, Eand F). Whereas in tumor-bearing mice groups, most of
cytokines were decreased after LF-MF exposure, including
KC, CCL1, IFN-γ, CXCL9, CXCL12, TREM-1, CCL12,
IL-1rα and IL-16. And the only increased cytokines was
IP-10 (Figure 5C, D, E and F).
LF-MF promotes T cells polarization in spleen
To detect whether the immune cells were regulated after
exposure to LF-MF, the proportions of T lymphocytes in
spleen cells was analyzed by flow cytometry. In normal
mice groups, there were no differences in the propor-
tions of CD3+, CD3 + CD4+ and CD3 + CD8+ T cells
between sham exposed and exposed groups. After chal-
lenged with B16-F10 in mice, the proportions of T cells
in spleen were significantly decreased from 49.15% to
18.64% for CD3+ T cells (Additional file 3: Figure S3A),
from 26.35% to 8.99% for CD3 + CD4+ T cells (Add-
itional file 3: Figure S3B), and from 17.15% to 5.88% for
CD3 + CD8+ T cells (Figure 5C). After LF-MF exposure,
the proportions of CD3+, CD3 + CD4+ and CD3 + CD8+
T cells in tumor-bearing mice were increased to 24.0%,
Figure 5 LF-MF regulates the production of inflammatory cytokines in mice serum. Using 1 ml mixed serum of each group, cytokine
profiles from sham normal group (A), LF-MF Normal group (B), sham tumor group (C) and MF tumor group (D) were detected by cytokine array,
respectively. The high-intensity spots in the three corners are positive controls (PC). In A and B, selected cytokines are labeled: red, cytokines that
increased compared with sham normal group; blue, cytokines that decreased compared with sham normal group; In C and D, selected cytokines
are labeled: red, cytokines that increased compared with sham normal group; blue, cytokines that decreased compared with sham normal group.
(E) and (F) show the mean IOD for each group.
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B and C).
LF-MF prevents Treg cell differentiation in spleen
After exposure to LF-MF, CD3 + CD4+ T cells signifi-
cantly increased in tumor-bearing mice. Treg is known
as a pro-tumor T cell [16]. Then the proportion of Treg
cells in spleen was analyzed by flow cytometry. As
shown in Figure 6A and B, the proportion of Treg cells
in sham normal mice spleen was 16.15% of all CD4+ T
cells, while sham tumor-bearing mice exhibited a 1.74-
fold increase of Treg cells (28.1% of the CD4+ popula-
tion). After exposed to LF-MF, the proportion of Treg
cells in normal mice (17.5% of the CD4+ population)
had not increase compared with sham normal mice,
while the proportion of Treg cells in tumor-bearing mice
was declined to 22.2%, which was significantly less than
that in sham MF tumor mice.
LF-MF enhances the expression of CD40 in dendritic cells.
We further tested the alteration of dendritic cells (DC)
after exposure to LF-MF. We found that the percentage
of DC in spleen, characterized by CD11c + expression,
was significantly increased in LF-MF normal mice
(9.57% of spleen lymphocytes) and sham LF-MF tumor-
bearing mice (9.75% of spleen lymphocytes), compared
with the sham normal mice (7.03% of spleen lympho-
cytes). In LF-MF tumor-bearing mice, the percentage ofDC was closed to the sham tumor-bearing mice, about
10.63% of spleen lymphocytes (Figure 6C and D). More-
over, we also examined the expression of CD40 on DC.
After exposure to LF-MF, the percentage of CD40+ DC
was significantly increased in both normal mice and
tumor-bearing mice, from 0.72% to 1.19%, and from
1.25% to 1.98%, respectively (Figure 6C and E).
Discussion
Treatment of melanoma is a major challenge due to the
limited number of therapeutic options available. In the
present study, we explored the tumor inhibitory effect of
LF-MF (0.4 T, 7.5Hz) in melanoma B16-F10 cell line and
melanoma lung metastasis, and found that the LF-MF
inhibited the proliferation in B16-F10 cells and induced
a G2/M-phase arrest. The LF-MF also influenced the
ultrastructure of B16-F10 cells. Furthermore, we found
that survival rate of B16-F10-challenged mice was im-
proved after LF-MF exposure, and the tumor prolifera-
tion in lung was also inhibited. In addition, the function
of innate immune cells and adaptive immune cells was
significantly modulated after LF-MF exposure.
LF-MF (0.4 T, 7.5 Hz) inhibited the growth of cancer
cells, which is consistent with our previous study [15]. It
was reported that MF inhibited the cell growth by pro-
moting apoptosis and arranging the cell cycle [17-19]. Tt
is thus clear that the inhibitory effect of MF was signifi-
cant but not specific in melanoma. Moreover, the LF-
Figure 6 LF-MF prevents Treg cell differentiation and enhance the expression of CD40 in dendritic cells in spleen. (A) Flow cytometry
analyzes the population of Treg cells in total CD4+ cells in splenetic lymphocytes; (B) the mean percentage of CD4 + Foxp3+ T lymphocytes in
CD4+ T cells for each group; (C) Flow cytometry analyzes CD11c + CD40+ dendritic Cells (DC) proportion in splenetic lymphocytes for each
group. (D) The mean proportion of CD11c + DCs in splenetic lymphocytes for each group. (E) The mean proportion of CD11c + CD40+ DCs in
splenetic lymphocytes for each group. All the experiments were repeated three times. Data are expressed as means ± S.E.M.
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of cells from S to G2/M phase of the cell cycle. The apop-
tosis cells were slightly increased after 5 days exposure to
LF-MF. However, the expression of genes associated apop-
tosis (Bcl2 and Survivin) showed no difference between
sham LF-MF and LF-MF group. This result suggests that
the inhibitory effect of LF-MF may not mainly be attrib-
uted to the induction of apoptosis. As is well known, both
apoptosis and autophagy may also play an important role
in the inhibitory effect of LF-MF. Thus, it will be needed
to explore other supporting experiments such as BrdU
labeling and TUNEL in further study. In addition, B16-
F10 cell exhibited significant ultrastructural changes afterexposure to LF-MF for 5 days, including the parted cell
chromatin and the accumulation of black granules. Previ-
ous studies reported that static magnetic fields affected
cell ultrastructure [20]. These results imply the cells may
undergo lysis and apoptosis and the aging of B16-F10 may
be improved after this LF-MF exposure.
The survival rate of melanoma model mice was ele-
vated after LF-MF exposure, which is in agreement with
the previous studies [2]. It was reported that the lung
metastases were the primary characteristics after intra-
venous challenge of C57BL/6 mice with melanoma cells
[21]. Furthermore, we detected broadly expression of
Ki-67 the lungs of tumor mice by immunohistochemistry
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cantly decreased after LF-MF exposure. It is known that
Ki-67 protein is a cellular marker for proliferation and
strictly associated with cell proliferation [22]. In addition,
the abnormal tumefaction of spleen and kidney in tumor
challenging mice were modulated after LF-MF exposure.
Spleen tumefaction is a familiar phenomenon in tumor
challenging mice. The modulative effect of LF-MF on
spleen in B16-F10 challenging mice suggests that the LF-
MF may reverse the effect of intravenous B16-F10 cells.
These results are in agreement with previous studies that
static and LF-MF-induced inhibition of human breast
adenocarcinoma, but not embryonal lung fibroblast [23].
As the most important surveillance in organism, im-
mune system has three primary roles in the prevention
of tumors: protect the host from virus-induced tumors,
prevent the establishment of an inflammatory environ-
ment conducive to tumorigenesis and specifically iden-
tify and eliminate tumor cells [24]. On the other hand,
immune surveillance is not always successful, tumors
can escape immune surveillance and ‘edit’ immune sys-
tem to block antitumor adaptive and innate responses
and promote tumor progression. It is believed that Treg
cells have the potent ability to suppress host immune re-
sponses and tumor cells can recruit Treg cells to inhibit
anti-tumor immunity in the tumor microenvironment,
thus helping the tumor escape from the immune surveil-
lance [16]. In this study, we found that the frequency of
T cells and DCs in mice was significantly increased after
LF-MF exposure, while the number of Treg cells was de-
creased. Furthermore, the LF-MF abolished the benefit
factors for tumor growth and slowed the growth of the
tumor. The anti-tumor cytokine, IP-10 [25], was signifi-
cantly accumulated, while the pro-tumor cytokines, KC
[26], CCL1 [27], CCL12 [28] and CXCL12 [29] were de-
creased after LF-MF exposure. In addition, we also found
that T cells in the spleen were significantly changed in
mice with tumor, but LF-MF affected the proportion of
different T cells in spleen. this suggests that spleen, as an
important immune organ, may be involved in anti-tumor
role during LF-MF treatment. All these results support
our hypothesis that the LF-MF may modulate the immune
response and inhibit the growth of cancer cells. However,
the biological function of T cell alteration during LF-MF
treatment will be needed to clarify in the following study.
Conclusions
In conclusion, our present study demonstrated that the
LF-MF (0.4 T, 7.5 Hz) inhibited the growth of B16-F10
in vitro. Furthermore, the LF-MF elevated the survival
rate, and inhibited the proliferation of B16-F10 cells in
lung metastasis model mice. The inhibition in vitro may
be attributed to the suppression of proliferation, in-
crease of G2/M phase, slightly induction of apoptosisand decomposition of the chromatins. The LF-MF also
modulated the immune response including the levels of
cytokine production and functions of innate immune
cells and adaptive immune cells. The elevation of sur-
vival rate in tumor-bearing mice may be related to the
improvement of immune function. Taken together, our
study proved that LF-MF inhibits the growth of melan-
oma and may provide a potential therapy for treatment
of melanoma.Additional files
Additional file 1: Figure S1. LF-MF influences cell apoptosis and
expression of apoptotic associate genes in B16-F10. (A) and (B) Flow
cytometric analysis of apoptosis in B16-F10 cells after exposure to LF-MF
for 3, 4 and 5 days. Relative exprssion of Bcl2 (C) and Survivin (D) in B16-F10
after exposure to LF-MF. Data are expressed as means ± S.E.M.
Additional file 2: Figure S2. LF-MF modulates the masses of the mice
organs. (A) Images showing spleen enlarge after intravenous challenge of
C57BL/6 mice with B16-F10 cells and treatment with LF-MF for 43 days.
The mean weights of spleen for each group are depicted to the right of
the image. (C), (D), (E) and (F) show the mean weights of lung, liver,
kidney and heart for each group. (B) HE analysis of spleen in different
groups. Data are expressed as means ± S.E.M.
Additional file 3: Figure S3. LF-MF promotes T lymphocytes
polarization in spleen. Flow cytometry analyzes CD3+ (A, left), CD3 + CD4+
(B, left) and CD3 + CD8+ (C, left) T lymphocytes in splenetic lymphocytes for
each group. The mean percentage of CD3+, CD3 + CD4+ and CD3 + CD8+
T lymphocytes in splenetic lymphocytes for each group are depicted to the
right of the images. Three independent experiments were carried out. Data
are expressed as means ± S.E.M.Competing interests
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